dr reddy's glp-1 drugs portfolio 2025 Reddys eyes global market with generic drug rollout on patent expiry | Hyderabad News Q&A: Dr. Reddy's CEO on

Effect of Liraglutide 3.0 Mg in Individuals With Obesity and Moderate or Severe Obstructive Sleep Apnea: The Scale Sleep Apnea Randomized Clinical Trial

Novo nordisk files for regulatory approval of once-weekly semaglutide with the fda for the treatment of type 2 diabetes

Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

Individual GLP-1 medications compared to phentermine Rather than treating GLP-1 medications as a monolithic category, it helps to examine how each individual GLP-1 drug stacks up against phentermine on its own terms